GlassScriptPhysician profile
Inna Abramova
NPI 1467487801
$8,804.49
in general payments reported to CMS, 2019-2025
37 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $993 · 2021: $1,333 · 2022: $1,564 · 2023: $1,096 · 2024: $1,349 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.64 | 2020-2025 | Vraylar, Linzess, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $733.75 | 2019-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $670.61 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $550.28 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $500.42 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $493.96 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| E.R. Squibb & Sons, L.L.C. | $432.95 | 2019-2025 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $400.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $328.20 | 2021-2024 | |
| Allergan, INC. | $325.02 | 2019-2020 | |
| Amarin Pharma, INC. | $285.04 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $270.11 | 2019-2022 | |
| Pfizer INC. | $247.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $221.34 | 2019-2025 | Verquvo, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.54 | 2019-2024 | Trulance, Xifaxan |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Abramova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.